Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are promising targeted therapeutics for breast and ovarian cancers bearing a germline BRCA1/2 mutation (BRCA (m)), and several have already received regulatory approval in the United States. In patients with a BRCA (m) cancer, PARPi can increase...

全面介紹

Na minha lista:
書目詳細資料
發表在:Am J Cancer Res
Main Authors: Han, Ye, Chen, Mei-Kuang, Wang, Hung-Ling, Hsu, Jennifer L, Li, Chia-Wei, Chu, Yu-Yi, Liu, Chun-Xiao, Nie, Lei, Chan, Li-Chuan, Yam, Clinton, Wang, Shao-Chun, He, Gui-Jin, Hortobagyi, Gabriel N, Tan, Xiao-Dong, Hung, Mien-Chie
格式: Artigo
語言:Inglês
出版: e-Century Publishing Corporation 2019
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448061/
https://ncbi.nlm.nih.gov/pubmed/30949414
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍